Ambrx Biopharma ROA 2020-2021 | AMAM

Current and historical return on assets (ROA) values for Ambrx Biopharma (AMAM) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Ambrx Biopharma ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.095B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00